Engineered nanocultures with egg like shells host thousands of microbes and burst on cue, offering precise, high throughput tools for microbiome research in tough environments.

There's a new player on the antibody-drug conjugate (ADC) scene. UK-based Pheon Therapeutics has entered stage right with $68 million in funding that will be used to fund development of a pipeline of ...